Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V A Johnson

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Annals of Internal Medicine|June 15, 1996
Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 InvestigatorsR T D'Aquila, M D Hughes, V A Johnson, et al.
Annals of Internal Medicine|March 15, 1995
Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working GroupR T D'Aquila, V A Johnson, S L Welles, et al.
Nature Ecology & Evolution|June 24, 2020
Microbial transmission in animal social networks and the social microbiomeAmar Sarkar, Siobhán Harty, Katerina V-A Johnson, et al.
Annals of Internal Medicine|June 15, 1997
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy TeamM D Hughes, V A Johnson, M S Hirsch, et al.
AIDS (London, England)|July 9, 1999
Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 InvestigatorsD R Kuritzkes, I Marschner, V A Johnson, et al.
AIDS (London, England)|September 13, 2000
Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370D R Kuritzkes, R L Bassett, V A Johnson, et al.
JAMA|June 27, 1998
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA PanelM S Hirsch, B Conway, R T D'Aquila, et al.
JAMA|May 18, 2000
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA PanelM S Hirsch, F Brun-Vézinet, R T D'Aquila, et al.
The Journal of Infectious Diseases|January 7, 1998
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapyI C Marschner, A C Collier, R W Coombs, et al.
The Journal of Infectious Diseases|October 1, 1996
Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working GroupsR W Coombs, S L Welles, C Hooper, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Annals of Internal Medicine|June 15, 1996
Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 InvestigatorsR T D'Aquila, M D Hughes, V A Johnson, et al.
Annals of Internal Medicine|March 15, 1995
Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working GroupR T D'Aquila, V A Johnson, S L Welles, et al.
Nature Ecology & Evolution|June 24, 2020
Microbial transmission in animal social networks and the social microbiomeAmar Sarkar, Siobhán Harty, Katerina V-A Johnson, et al.
Annals of Internal Medicine|June 15, 1997
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy TeamM D Hughes, V A Johnson, M S Hirsch, et al.
AIDS (London, England)|July 9, 1999
Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 InvestigatorsD R Kuritzkes, I Marschner, V A Johnson, et al.
AIDS (London, England)|September 13, 2000
Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370D R Kuritzkes, R L Bassett, V A Johnson, et al.
JAMA|June 27, 1998
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA PanelM S Hirsch, B Conway, R T D'Aquila, et al.
JAMA|May 18, 2000
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA PanelM S Hirsch, F Brun-Vézinet, R T D'Aquila, et al.
The Journal of Infectious Diseases|January 7, 1998
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapyI C Marschner, A C Collier, R W Coombs, et al.
The Journal of Infectious Diseases|October 1, 1996
Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working GroupsR W Coombs, S L Welles, C Hooper, et al.
Pageof 10